In this study, we demonstrated that inhibition of DEC2 restored, at least in part, sensitivity of hypoxic cancer cell lines to bleomycin or radiation treatment, suggesting a potential molecular target for modifying DNA damage-inducing treatments. The gene discussed is BHLHE41; the disease is cancer.